Journals / Retina-Vitreus / 2014 / Cilt: 22 - Sayı: 1

The effect of ıntravitreal ranibizumab treatment for exudative age-related macular degeneration with good visual acuity

İyi gören yaşa bağlı maküla dejenerasyonlu hastalarda erken ranibizumab tedavisinin etkinliği

Pages
35–39
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Prompt intravitreal ranibizumab treatment for newly diagnosed AMD in patients with good initial BCVA is associ- ated with sustained or improved vision and a good safety profile.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To investigate the effect of intravitreal ranibizumab on the visual acuity of patients with exudative age-related macu- lar degeneration (AMD) presenting with good visual acuity (VA).
📊
Key Findings & Data:Materials and Methods: A file review was performed for all consecutive patients with newly diagnosed exudative age-related macular degeneration and initial VA of ≥8/10 treated in 2009 to 2013 and followed for at least 6 months.
💡
Conclusion & Impact:Conclusion: Prompt intravitreal ranibizumab treatment for newly diagnosed AMD in patients with good initial BCVA is associ- ated with sustained or improved vision and a good safety profile.
🔬Design:Review & Systematic Survey
📍Scope:2009 Verileri
⚙️Variables:Domain Parameters

Abstract

Purpose: To investigate the effect of intravitreal ranibizumab on the visual acuity of patients with exudative age-related macu- lar degeneration (AMD) presenting with good visual acuity (VA). Materials and Methods: A file review was performed for all consecutive patients with newly diagnosed exudative age-related macular degeneration and initial VA of ≥8/10 treated in 2009 to 2013 and followed for at least 6 months. Treatment consisted of 3 loading doses of intravitreal ranibizumab every 4 weeks and was repeated when decrease in best-corrected visual acuity (BCVA) or increase in central macular thickness (CMT) was present. Results: Mean follow-up was 16.1±11.6 months (6-38). Mean BCVA was 46.2±3.0 letters (45-55 letters) in ETDRS chart preop- eratively, whereas it was 49.3±4.7 letters (45-55 letters) in the last follow-up visit (p=0.018). Stabilization in BCVA was achieved in 53.6% of the study eyes, however the mean of 3.4 letters of increase in ETDRS chart was gained in 42.9% of the study eyes. Mean CMT was 352.1±127.3 μm (185-733 μm) preoperatively, whereas it was 289.9±70.1 μm (159-410 μm) in the last follow-up visit (p=0.007). Treatment was started approximately 1 month after the initial symptoms of exudative AMD in patients whose BCVA stabilized with 3 intravitreal ranibizumab injections, however treatment had been started 5 months after the initial symp- toms on average in patients who required additional intravitreal ranibizumab application. Conclusion: Prompt intravitreal ranibizumab treatment for newly diagnosed AMD in patients with good initial BCVA is associ- ated with sustained or improved vision and a good safety profile.

Özet

Amaç: İyi düzeyde görme keskinliğine sahip yaş tip yaşa bağlı maküla dejenerasyonlu (yaş tip YBMD) hastalarda intravit- real ranibizumab tedavisinin görme sonuçlarına olan etkisini incelemek. Gereç ve Yöntem: Görme keskinliği ≥8/10 olan ve intravitreal ranibizumab tedavisi uygulanmış yaş tip YBMD’li 28 has- ta, retrospektif olarak incelendi. Hastaların tedavi öncesinde düzeltilmiş en iyi görme keskinliği (DEİGK), santral maküla kalınlığı (SMK) ve koroidal neovaskülarizasyon tipi değerlendirildi. Üç doz standart (aylık aralıklarla) intravitreal ranibi- zumab uygulanması sonrasında hastalar aylık takibe alındı. Takipler sırasında DEİGK’de ve SMK’daki değişime göre ilave intravitreal ranibizumab uygulandı. Bulgular: Ortalama takip süresi 16.1±11.6 ay (6-38 ay) idi. İntravitreal ranibizumab enjeksiyonu uygulanmadan önce, tüm gözlerin ortalama DEİGK 46.2±3.0 harf (45-55 harf, ETDRS Eşeli), son muayenede ortalama DEİGK 49.3±4.7 harf (45-55 harf) olarak saptandı (p=0.018). Üç doz ranibizumab enjeksiyonu sonrasındaki aylık takiplerde 28 gözün %53.6’sınde sta- bilizasyon, %42.9’da ortalama 3.4 harf artışı sağlandı. İntravitreal ranibizumab enjeksiyonu öncesi bazal optik koherens tomografi (OKT) ortalama 352.1±127.3 μm (185-733 μm), son muayenede ortalama 289.9±70.1 μm (159-410 μm) olarak tespit edildi (p=0.007). İlave ranibizumab, 5 hastada 1 doz, 3 hastada ise 2 doz uygulandı. Semptomların başlaması ile tedaviye başlama zamanı arasındaki süre; 3 doz ile stabilize olan grupta ortalama 1 ay, ilave enjeksiyon gereken grupta ise ortalama 5 ay idi. İki grup arasında cinsiyet, ortalama yaş ve koroidal neovaskülarizasyon tipi yönünden istatistiksel anlamlı fark bulunmadı. Sonuç: İyi gören yaş tip YBMD hastalarda, görme keskinliğinin iyi olmasının tedaviyi erteleme nedeni olmadığı, tedaviye olabildiğince erken başlamanın hem hastalığın hem de görme keskinliğinin stabilizasyonunda etkili olduğu gözlendi.

🔖

Cite This Article

KOÇAK, N., KAYA, M., UYAR, M. G., ÖZTÜRK, A. T., KAYNAK, S. (2014). The effect of ıntravitreal ranibizumab treatment for exudative age-related macular degeneration with good visual acuity. Retina-Vitreus, Cilt: 22 - Sayı: 1, 35–39. https://ajindex.com/articles/305040

References (14)

  1. Miller JW, Schmidt-Erfurth U, Sickenberg M, et al. Photody- namic therapy withverteporfin for choroidal neovasculariza- tion caused by age-related macular degeneration: results of a single treatment in a phase I and II study. Arch Ophthalmol 1999;117:1177-87
  2. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992;99:933-43
  3. Green WR,Wilson DJ. Choroidal neovascularization. Oph- thalmology 1986;93:1169-76
  4. Klein R, Klein BEK, Linton KP. The Beaver Dam Eye Study: the relation of age-related maculopathy to smoking 1993. Am J Epidemiol 1993;137:190-200
  5. Pauliekhoff D, Spital G, Radermacher M et al. A fluores- cein and indocyanine green angiographic study of chorio- capillaris in age-related macular disease. Arch Opthalmol 1999;117:1353-8
  6. Barouch FC, Miller JW. Anti-vascular endothelial growth fac- tor strategies for the treatment of choroidal neovasculariza- tion from age-related macular degeneration. Int Ophthalmol Clin 2004;44:23-32
  7. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 2005;40:352-68
  8. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-re- lated macular degeneration: PIER Study year 2. Am J Oph- thalmol 2010;150:315-24
  9. Brown DM, Kaiser PK, Michels M; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. The New England Journal of Medicine 2006;35:1432-44
  10. Rosenfield PJ, Schwartz SD, Blumenkranz M, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005;112:1048-53
  11. Krzystolik MG, Afsari MA, Adamis PA et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120:338-46
  12. Koçak N, Kaya M, Selver ÖB, ve ark. Koroid neovaskül- arizasyonunda ranibizumab monoterapisinin erken dönem sonuçları. Turk J Ophthalmol 2011;41:10-15
  13. Rosenfeld PJ, Brown DM, Heier JS, et al (MARINA Study Group). Ranibizumab for neovascular age-related macular de- generation. N Engl J Med 2006;355:1419-31
  14. Şengül A, Artunay Ö, Yüzbaşioğlu E ve ark. Yaşa bağlı maküla dejenerasyonuna ikincil gelişen koroid neovaskülarizasyonlarında intravitreal ranibizumab tedavi so